Curative Biosciences Company Insiders
| CBDX Stock | USD 0.0001 0.00 0.00% |
Curative Biosciences employs about 5 people. The company is managed by 4 executives with a total tenure of roughly 19 years, averaging almost 4.0 years of service per executive, having 1.25 employees per reported executive. Break down of Curative Biosciences' management performance can provide insight into the company performance.
| Richard Damion CEO CEO, Director |
Curative |
Curative Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (38.439) % which means that it has lost $38.439 on every $100 spent on assets. This is way below average. Curative Biosciences' management efficiency ratios could be used to measure how well Curative Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Curative Biosciences Workforce Comparison
Curative Biosciences is number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 12.0. Curative Biosciences totals roughly 5.0 in number of employees claiming about 42% of equities under Drug Manufacturers—Specialty & Generic industry.
Curative Biosciences Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Curative Biosciences Price Series Summation is a cross summation of Curative Biosciences price series and its benchmark/peer.
Curative Biosciences Notable Stakeholders
A Curative Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Curative Biosciences often face trade-offs trying to please all of them. Curative Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Curative Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Richard Damion | CEO, Director | Profile | |
| William Lindberg | CFO Director | Profile | |
| A Grandsaert | President | Profile | |
| Katherine West | Chairwoman of the Board | Profile |
About Curative Biosciences Management Performance
The success or failure of an entity such as Curative Biosciences often depends on how effective the management is. Curative Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Curative management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Curative management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. Curative Biosciences, Inc. was founded in 2009 and is based in Miami, Florida. Curative Biosciences is traded on OTC Exchange in the United States.
Please note, the imprecision that can be found in Curative Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Curative Biosciences. Check Curative Biosciences' Beneish M Score to see the likelihood of Curative Biosciences' management manipulating its earnings.
Curative Biosciences Workforce Analysis
Traditionally, organizations such as Curative Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Curative Biosciences within its industry.Curative Biosciences Manpower Efficiency
Return on Curative Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 10.6K | |
| Net Loss Per Executive | 13.3K |
Additional Tools for Curative Pink Sheet Analysis
When running Curative Biosciences' price analysis, check to measure Curative Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biosciences is operating at the current time. Most of Curative Biosciences' value examination focuses on studying past and present price action to predict the probability of Curative Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biosciences' price. Additionally, you may evaluate how the addition of Curative Biosciences to your portfolios can decrease your overall portfolio volatility.